A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India

Locations

India

Start date

26/08/2025

Identifiers

Trial ID NN7711-7717,
NCT number NCT07157423,
Eudract number Not Available

Summary

This study will look at how safe is the medicine eptacog alfa when used in women in India for stopping heavy bleeding after giving birth. If participants have heavy bleeding after giving birth then they will get the medicine eptacog alfa. This study will be conducted to get more knowledge on the safety of the medicine eptacog alfa use in these women. At first participants will receive one dose of medicine eptacog alfa. If the given dose is not helpful to stop the bleeding, participants will get one additional dose. The study will last for about 30-35 days.

Trial Overview:

Condition

Severe Postpartum Haemorrhage

Treatment

DRUG: Eptacog alfa (NovoSeven)

Study type

INTERVENTIONAL

Trial duration

Aug 26 2025 - Mar 26 2027

Participants

Phase

IIII

Are you eligible?

Gender

FEMALE

Age

18 years and older

Find out how you can participate

Questions or concerns

Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.

Find answers in our FAQs

This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.